Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...
Skin disorders are a common extraintestinal symptom of inflammatory bowel disease (IBD), occurring in up to 25% of people with ulcerative colitis and Crohn's disease. Some of these skin conditions are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback